17-7-4　ⓔ文献

  1. Majzner RG, Mackall CL: Clinical lessons learned from the first leg of the CAR T cell journey. Nat Med, 2019; 25: 1341–1355.

  2. June CH, Sadelain M: Chimeric antigen receptor therapy. N Engl J Med, 2018; 379: 64–73.

  3. Chapuis AG, Egan DN, et al: T cell receptor gene therapy targeting WT1 prevents acute myeloid leukemia relapse post–transplant. Nat Med, 2019; 25: 1064–1072.

  4. Finney OC, Brakke HM, et al: CD19 CAR T cell product and disease attributes predict leukemia remission durability. J Clin Invest, 2019; 129: 2123–2132.

  5. Maude SL, Laetsch TW, et al: Tisagenlecleucel in children and young adults with B–cell lymphoblastic leukemia. N Engl J Med, 2018; 378: 439–448.

  6. Schuster SJ, Bishop MR, et al: Tisagenlecleucel in adult relapsed or refractory diffuse large B–cell lymphoma. N Engl J Med, 2019; 380: 45–56.

  7. Lee DW, Santomasso BD, et al: ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant, 2019; 25: 625–638.

  8. Turtle CJ, Hanafi LA, et al: CD19 CAR–T cells of defined CD4＋: CD8＋ composition in adult B cell ALL patients. J Clin Invest, 2016; 126: 2123–2138.

  9. Gardner RA, Finney O, et al: Intent–to–treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults. Blood, 2017; 129: 3322–3331.

  10. Crump M, Neelapu SS, et al: Outcomes in refractory diffuse large B–cell lymphoma: results from the international SCHOLAR–1 study. Blood, 2017; 130: 1800–1808.

  11. Neelapu SS, Locke FL, et al: Axicabtagene Ciloleucel CAR T–Cell Therapy in Refractory Large B–Cell Lymphoma. N Engl J Med, 2017; 377: 2531–2544.

  12. Turtle CJ, Hanafi LA, et al: Immunotherapy of non–Hodgkin’s lymphoma with a defined ratio of CD8＋ and CD4＋ CD19－ specific chimeric antigen receptor–modified T cells. Sci Transl Med, 2016; 8: 355ra116.

  13. Kochenderfer JN, Somerville RPT, et al: Lymphoma remissions caused by anti–CD19 chimeric antigen receptor T cells are associated with high serum interleukin–15 Levels. J Clin Oncol, 2017; 35: 1803–1813.

  14. Locke FL, Ghobadi A, et al: Long–term safety and activity of axicabtagene ciloleucel in refractory large B–cell lymphoma (ZUMA–1): a single–arm, multicentre, phase 1–2 trial. Lancet Oncol, 2019; 20: 31–42.

  15. Turtle CJ, Hay KA, et al: Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19–Specific Chimeric Antigen Receptor–Modified T Cells After Failure of Ibrutinib. J Clin Oncol, 2017; 35: 3010–3020.

  16. Porter DL, Hwang WT, et al: Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci Transl Med, 2015; 7: 303ra139.

  17. Sidana S, Shah N: CAR T–cell therapy: is it prime time in myeloma? Blood Adv, 2019; 3: 3473–3480.

  18. Brudno JN, Maric I, et al: T Cells Genetically Modified to Express an Anti-B–Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor–Prognosis Relapsed Multiple Myeloma. J Clin Oncol, 2018; 36: 2267–2280.

  19. Raje N, Berdeja J, et al: Anti–BCMA CAR T–Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma. N Engl J Med, 2019; 380: 1726–1737.

  20. Mueller KT, Waldron E, et al: Clinical pharmacology of tisagenlecleucel in B–cell acute lymphoblastic leukemia. Clin Cancer Res, 2018; 24: 6175–6184.

  21. Gardner RA, Ceppi F, et al: Preemptive mitigation of CD19 CAR T–cell cytokine release syndrome without attenuation of antileukemic efficacy. Blood, 2019; 134: 2149–2158.